HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sáenz de Tejada, I. Articles by Emmick, J. T. Search for Related Content PubMed PubMed Citation Articles by Sáenz de Tejada, I. Articles by Emmick, J. T. Social Bookmarking                What's this?

Effects of Tadalafil on Erectile Dysfunction in Men With Diabetes

¹ Fundacíon para la Investigacíon y el Desarrollo en Andrología, Madrid, Spain
² Eli Lilly Canada, Toronto, Ontario, Canada
³ Eli Lilly and Company, Indianapolis, Indiana

OBJECTIVE—To evaluate the efficacy and safety of tadalafil taken as needed before sexual activity by men with diabetes and erectile dysfunction (ED).

RESEARCH DESIGN AND METHODS—Men with type 1 or type 2 diabetes and a minimum 3-month history of ED were randomly allocated to one of three groups: placebo (n = 71), tadalafil 10 mg (n = 73), or tadalafil 20 mg (n = 72) taken up to once daily for 12 weeks. Changes from baseline in mean scores on the erectile function domain of the International Index of Erectile Function (IIEF) and changes from baseline in the proportion of "yes" responses to question 2, "Were you able to penetrate?," and 3, "Were you able to complete intercourse?," of the Sexual Encounter Profile were coprimary outcome measures.

RESULTS—A total of 191 (88%) of 216 patients completed the study. Treatment with tadalafil significantly improved all primary efficacy variables, regardless of baseline HbA_1c level. Therapy with tadalafil also significantly improved a number of secondary outcome measures, including changes in other IIEF domains, individual IIEF questions, and percentage of positive responses to a global assessment question measuring erection improvement. Treatment with tadalafil did not alter mean HbA_1c levels. Tadalafil was well tolerated, with headache and dyspepsia being the most frequent adverse events with active treatment.

CONCLUSIONS—Tadalafil therapy significantly enhanced erectile function and was well tolerated by men with diabetes and ED.

Abbreviations: ECG, electrocardiogram • ED, erectile dysfunction • GAQ, global assessment question • IIEF, International Index of Erectile Function • NO, nitric oxide • PDE5, phosphodiesterase type 5 • SEP, Sexual Encounter Profile

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. M Setter, J. L Iltz, J. E Fincham, R K. Campbell, and D. E Baker Phosphodiesterase 5 Inhibitors for Erectile Dysfunction Ann. Pharmacother., July 1, 2005; 39(7): 1286 - 1295. [Abstract] [Full Text] [PDF]

				A. J.M. Boulton, A. I. Vinik, J. C. Arezzo, V. Bril, E. L. Feldman, R. Freeman, R. A. Malik, R. E. Maser, J. M. Sosenko, and D. Ziegler Diabetic Neuropathies: A statement by the American Diabetes Association Diabetes Care, April 1, 2005; 28(4): 956 - 962. [Full Text] [PDF]

				J. S. Brown, H. Wessells, M. B. Chancellor, S. S. Howards, W. E. Stamm, A. E. Stapleton, W. D. Steers, S. K. Van Den Eeden, and K. T. McVary Urologic Complications of Diabetes Diabetes Care, January 1, 2005; 28(1): 177 - 185. [Full Text] [PDF]

				D. F. Penson and H. Wessells Erectile Dysfunction in Diabetic Patients Diabetes Spectr, October 1, 2004; 17(4): 225 - 230. [Abstract] [Full Text] [PDF]

				C. C. Carson Erectile Dysfunction: Evaluation and New Treatment Options Psychosom Med, September 1, 2004; 66(5): 664 - 671. [Abstract] [Full Text] [PDF]

				D. A. Norwood, N. E. Eraikhuemen, M. Larose-Pierre, E. Branch III, and R. M. Norwood Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil Journal of Pharmacy Practice, August 1, 2004; 17(4): 239 - 250. [Abstract] [PDF]

				New oral drugs for erectile dysfunction DTB, July 1, 2004; 42(7): 49 - 52. [Abstract] [Full Text] [PDF]

				L. Fazio and G. Brock Erectile dysfunction: management update Can. Med. Assoc. J., April 27, 2004; 170(9): 1429 - 1437. [Abstract] [Full Text] [PDF]

				D. O. Sussman Pharmacokinetics, Pharmacodynamics, and Efficacy of Phosphodiesterase Type 5 Inhibitors J Am Osteopath Assoc, March 1, 2004; 104(3_suppl): 11S - 15S. [Abstract] [Full Text]